AssetMark Inc
COGT icon

AssetMark Inc’s Cogent Biosciences COGT Stock Holding History

AssetMark Inc’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$548K Sell
17,114
-1,165
-6% -$43K ﹤0.01% 1227
2026
Q2 		$707K Sell
18,279
-708
-4% -$24.8K ﹤0.01% 1153
2026
Q1 		$731K Buy
+18,987
New +$701K ﹤0.01% 1091

Other funds holding COGT

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

AssetMark Inc's COGT Position: Q3 2026 in Review

AssetMark Inc reduced its Cogent Biosciences (COGT) stake by 6.4% in Q3 2026, selling an estimated $43K and leaving 17,114 shares worth $548K. The position accounts for ﹤0.01% of the portfolio, ranked #1227.

AssetMark Inc first reported a position in COGT in Q1 2026 and has held it in 3 quarters since. The position peaked at $731K in Q1 2026. 76 funds tracked by Wall St. Rank hold COGT as of Q3 2026.

  • AssetMark Inc held 17,114 shares of Cogent Biosciences worth $548K as of Q3 2026.
  • AssetMark Inc sold 1,165 Cogent Biosciences shares in Q3 2026, an estimated $43K.
  • Cogent Biosciences made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #1227 holding.
  • AssetMark Inc first reported a position in Cogent Biosciences in Q1 2026 and has held it in 3 quarters since.
  • AssetMark Inc's Cogent Biosciences position peaked at $731K in Q1 2026.
  • 76 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.